Compare Biogen Inc (BIIB) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs PulteGroup, Inc. — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while PulteGroup, Inc. trades at $132.77 (market cap $25.22B). The key difference: Biogen Inc is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.79% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PHM | |
|---|---|---|
Market Cap | $30.13B | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $142.56 |
52-Week Low | $128.93 | $110.11 |
Enterprise Value | $37.20B | $25.64B |
Dividend Yield | — | 0.79% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
